Henry B. Lowman
94Patents
26h-index
68Co-inventors
91Inventor score
Filing activity: Apr 30, 1993 → Nov 22, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5750373A | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants | Emerging Cross-Sectional Technologies | 617 | Expired |
| US5821047A | Monovalent phage display | Emerging Cross-Sectional Technologies | 534 | Expired |
| US7521541B2 | Cysteine engineered antibodies and conjugates | Chemistry; Metallurgy | 445 | Expired |
| US7060269B1 | Anti-VEGF antibodies | Chemistry; Metallurgy | 159 | Expired |
| US5849535A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 153 | Expired |
| US7855275B2 | Cysteine engineered antibodies and conjugates | Chemistry; Metallurgy | 145 | Active |
| US5534617A | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 | Emerging Cross-Sectional Technologies | 130 | Expired |
| US5994511A | Anti-IgE antibodies and methods of improving polypeptides | Emerging Cross-Sectional Technologies | 117 | Expired |
| US6057292A | Method for inhibiting growth hormone action | Emerging Cross-Sectional Technologies | 101 | Expired |
| US5688666A | Growth hormone variants with altered binding properties | Physics | 101 | Expired |
| US7169901B2 | Anti-VEGF antibodies | Chemistry; Metallurgy | 94 | Expired |
| US7799900B2 | Immunoglobulin variants and uses thereof | Chemistry; Metallurgy | 86 | Active |
| US8309300B2 | Cysteine engineered antibodies and conjugates | Chemistry; Metallurgy | 81 | Active |
| US7365166B2 | Anti-VEGF antibodies | Chemistry; Metallurgy | 73 | Active |
| US6040136A | Enrichment method for variant proteins with altered binding properties | Emerging Cross-Sectional Technologies | 65 | Expired |
| US8562992B2 | Immunoglobulin variants and uses thereof | Chemistry; Metallurgy | 65 | Active |
| US5834598A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 65 | Expired |
| US7297334B2 | Anti-vegf antibodies | Chemistry; Metallurgy | 62 | Expired |
| US6632926B1 | Antibody variants | Chemistry; Metallurgy | 60 | Expired |
| US6172213A | Anti-IgE antibodies and method of improving polypeptides | Chemistry; Metallurgy | 56 | Expired |
| US6022711A | Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1 | Emerging Cross-Sectional Technologies | 52 | Expired |
| US6143523A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 51 | Expired |
| US7375193B2 | Anti-VEGF antibodies | Chemistry; Metallurgy | 44 | Active |
| US9120853B2 | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof | Physics | 39 | Active |
| US7435797B2 | Anti-HER2 antibody variants | Chemistry; Metallurgy | 38 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.